Leeds Teaching Hospitals NHS Trust (LTHT)

grid.415967.8

CQC Registered Health or/and Social Care provider

Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer, and when it spreads to other parts of the body (metastatic NSCLC), it can be difficult to treat. A newer type of treatment called immune checkpoint inhibitors (ICIs) has improved survival for some patients. However, most of what we know about these treatments comes from clinical trials, which may not fully reflect how they work in everyday healthcare settings around the world. This study looks at how people with metastatic NSCLC are treated in real life, across different countries and healthcare systems. By using data from patient records in the OMOP common data model and federated analysis, the study aims to understand how treatments are used, how outcomes differ between places, and how treatment patterns have changed since ICIs became available.

This study will provide important new insights into how metastatic lung cancer is treated across different healthcare settings worldwide. By using real-world data, it helps us understand how new treatments like immune checkpoint inhibitors are being used in practice and how they affect patient outcomes. The findings will support better treatment planning, more consistent care, and improved survival for people with advanced lung cancer, while also informing future policy and research.

01/12/2024

Yes

Federated analysis on OMOP database - no direct access to patient-level data